The company is working with the University of Florida Health Cancer Center to validate its RadTox QuantiDNA test as a monitor of cfDNA in patient plasma.
The Taiwanese research team that developed the method showed in a new study that it could better detect BRAF mutations than conventional PCR plus Sanger sequencing.
The state of California has given the lab permission to start offering its QClamp test to screen for tumor oncogenic driver and resistance mutations in tumor DNA.
DiaCarta will have the exclusive rights to develop a test for the early detection of colon cancer from stool samples and to commercialize it globally.
In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.
Technology Review points out that a new US presidential science advisor hasn't been selected.
Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.
President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.